Fig. 2: HMGB3 promotes olaparib resistance in ovarian cancer.
From: HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer
A PLKO.1, HMGB3 shRNA (shHMGB3), PCMV, and PCMV HMGB3 plasmids were stably transfected into A2780, SKOV3, and UWB1.289 cells. Western blot was used to determine HMGB3 protein levels. Quantification of HMGB3 protein levels can be found in Fig. S2. B The MTT assay was performed to detect cell viability in A2780, SKOV3, and UWB1.289 cells treated with olaparib (Ola) for 72 h. C Clonogenic assay was conducted to assess the colony formation efficiency of A2780, SKOV3, and UWB1.289 cells in the presence of olaparib for 7–14 days. D Quantification of the number of clones in (C). E Flow cytometry assay was performed to detect cell apoptosis in A2780 and UWB1.289 cells treated with olaparib (A2780, 4 µM; UWB1.289, 2 µM) for 72 h. F Quantification of the proportion of apoptotic cells in (E). (Data are presented as the mean ± SEM, #p > 0.05, *p < 0.05, **p < 0.01, n = 3).
